Chimerix Balance Sheet Health
Financial Health criteria checks 6/6
Chimerix has a total shareholder equity of $193.0M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $212.8M and $19.7M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$182.84m |
| Equity | US$193.03m |
| Total liabilities | US$19.75m |
| Total assets | US$212.77m |
Recent financial health updates
Here's Why We're Watching Chimerix's (NASDAQ:CMRX) Cash Burn Situation
Jul 20
Does Chimerix (NASDAQ:CMRX) Have A Healthy Balance Sheet?
Dec 24Is Chimerix (NASDAQ:CMRX) A Risky Investment?
Sep 16Does Chimerix (NASDAQ:CMRX) Have A Healthy Balance Sheet?
Jun 08Chimerix (NASDAQ:CMRX) Is In A Good Position To Deliver On Growth Plans
Dec 05Recent updates
Chimerix: Advancement For Rare Brain Cancer Drug Targeting Specific Mutation
Aug 23Here's Why We're Watching Chimerix's (NASDAQ:CMRX) Cash Burn Situation
Jul 20Chimerix: Down But Not Out
Jun 06Chimerix: Searching For Clarity
Jan 05Does Chimerix (NASDAQ:CMRX) Have A Healthy Balance Sheet?
Dec 24Is Chimerix (NASDAQ:CMRX) A Risky Investment?
Sep 16Does Chimerix (NASDAQ:CMRX) Have A Healthy Balance Sheet?
Jun 08Chimerix gets FDA approval for TEMBEXA for the treatment of smallpox
Jun 04Chimerix, Inc. (NASDAQ:CMRX): Are Analysts Optimistic?
May 13Chimerix Investor Presentation - Slideshow
May 08Chimerix expands oncology program with acquisition of Oncoceutics, shares up 10%
Jan 08Who Has Been Buying Chimerix, Inc. (NASDAQ:CMRX) Shares?
Jan 01
Chimerix rises 9.1% premarket after FDA accepts NDA for smallpox countermeasure
Dec 07Chimerix (NASDAQ:CMRX) Is In A Good Position To Deliver On Growth Plans
Dec 05Chimerix, Inc. 2020 Q3 - Results - Earnings Call Presentation
Nov 08Chimerix EPS misses by $0.01, beats on revenue
Nov 05Financial Position Analysis
Short Term Liabilities: CMRX's short term assets ($189.1M) exceed its short term liabilities ($18.4M).
Long Term Liabilities: CMRX's short term assets ($189.1M) exceed its long term liabilities ($1.3M).
Debt to Equity History and Analysis
Debt Level: CMRX is debt free.
Reducing Debt: CMRX had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: CMRX has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: CMRX has sufficient cash runway for 2.5 years if free cash flow continues to reduce at historical rates of 3.2% each year.